Immvira Bioscience Files Listing Application to Hong Kong Stock Exchange on July 16, Third Submission
According to Hong Kong Exchanges and Clearing disclosure on July 16, Immvira Bioscience Inc. submitted its listing application to the Main Board, with Citigroup and China International Capital Corporation as joint sponsors. The biotech company develops oncolytic immunotherapies and engineered
C0.85%
GateNews·07-16 10:36
